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Abstract
Introduction: Camptocormia refers to an abnormal posture with flexion of the thoraco-lumbar spine which increases 
during walking and resolves in supine position. This symptom is an increasingly recognized feature of parkinsonian and 
dystonic disorders, but may also be caused by neuromuscular diseases. There is recent evidence that both central and 
peripheral mechanisms may be involved in the pathogenesis of camptocormia. We report a case of acute onset of 
camptocormia, a rare side effect induced by olanzapine, a second-generation atypical anti-psychotic drug with fewer 
extra-pyramidal side-effects, increasingly used as first line therapy for schizophrenia, delusional disorders and bipolar 
disorder.
Case presentation: A 73-year-old Caucasian woman with no history of neuromuscular disorder, treated for chronic 
delusional disorder for the last ten years, received two injections of long-acting haloperidol. She was then referred for 
fatigue. Physical examination showed a frank parkinsonism without other abnormalities. Routine laboratory tests 
showed normal results, notably concerning creatine kinase level. Fatigue was attributed to haloperidol which was 
substituted for olanzapine. Our patient left the hospital after five days without complaint. She was admitted again 
three days later with acute back pain. Examination showed camptocormia and tenderness in paraspinal muscles. 
Creatine kinase level was elevated (2986 UI/L). Magnetic resonance imaging showed necrosis and edema in paraspinal 
muscles. Olanzapine was discontinued. Pain resolved quickly and muscle enzymes were normalized within ten days. 
Risperidone was later introduced without significant side-effect. The camptocormic posture had disappeared when 
the patient was seen as an out-patient one year later.
Conclusions: Camptocormia is a heterogeneous syndrome of various causes. We believe that our case illustrates the 
need to search for paraspinal muscle damage, including drug-induced rhabdomyolysis, in patients presenting with 
acute-onset bent spine syndrome. Although rare, the occurrence of camptocormia induced by olanzapine must be 
considered.
Introduction
Camptocormia (bent spine syndrome) refers to an abnor-
mal posture with marked flexion of the thoraco-lumbar
spine which increases during walking and resolves in
supine position. Originally attributed to psychogenic dis-
o r d e r s  ( w a r  h y s t e r i a ) ,  t h i s  s y m p t o m  i s  a n  i n c r e a s i n g l y
recognized feature of parkinsonian and dystonic disor-
ders, but it may also be caused by neuromuscular disor-
ders [1,2]. A fatty degeneration of paraspinal muscles has
been reported in some cases, giving support to the "myo-
pathic theory", but there is recent evidence that both cen-
tral and peripheral mechanisms may be involved in the
pathogenesis of camptocormia [3,4]. We report a case of
acute onset of camptocormia, with documented rhab-
domyolysis and marked abnormalities on paraspinal
muscular magnetic resonance imaging (MRI), probably
induced by olanzapine, a second-generation anti-psy-
chotic drug.
Case presentation
A 73-year-old Caucasian woman, who had been treated
for chronic delusional disorder for the last ten years,
received two injections of long-acting haloperidol. She
was then referred to the internal medicine department
for fatigue and anorexia. Physical examination showed a
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frank parkinsonism without other abnormalities. Routine
laboratory tests showed mild hypokalaemia, no renal dys-
function, normal muscle and liver enzymes, normal C-
reactive protein value and normal thyroid tests (Table 1).
The symptoms were attributed to the anti-psychotic
treatment, therefore haloperidol was withdrawn, and
substituted for olanzapine (5 mg/day). Our patient left
the hospital after five days of olanzapine treatment with-
out complaints. She was admitted again three days later
with acute back pain. Examination showed a characteris-
tic camptocormic posture (Figure 1) and tenderness in
paraspinal muscles. Creatine-kinase level was elevated as
were transaminases and C-reactive protein. Creatinine
level remained normal (Table 1). MRI of the spine
showed necrosis and edema in paraspinal muscles (Figure
2). Olanzapine was discontinued, pain resolved quickly
and muscle enzymes were normalized within ten days
(Table 1). A treatment with risperidone was later intro-
duced without significant side-effect. The camptocormic
posture had disappeared when our patient was seen as an
out-patient one year later. Laboratory tests showed no
abnormalities (Table 1). Our patient refused a control spi-
nal MRI.
Discussion
Olanzapine is one of the second-generation "atypical"
anti-psychotic drugs, with fewer extra-pyramidal side-
effects than conventional anti-psychotics, increasingly
used as first line therapy for schizophrenia and delusional
disorders [5]. Olanzapine has also been indicated for the
treatment of bipolar disorder. Olanzapine has been held
responsible for neuroleptic malignant syndrome, rhab-
domyolysis or elevation of serum creatine kinase, and
overdose of olanzapine is associated with acute muscle
Table 1: History of the treatment and biological data (ND: not done)






Haloperidol Olanzapine No treatment Risperidone
Biological data Normal values
Sodium 135 139 140 ND 136-146mEq/L
Potassium 2.7 3.6 4.4 ND 3.5-4.5mEq/L
Creatinine 59 61 69 ND 50-100 μmol/L
Aspartate aminotransferase 16 130 22 ND 0-45 U/L
Alanine aminotransferase 18 44 38 ND 0-45 U/L
Creatine kinase 44 2986 20 31 20-120 U/L
Creactive protein 17.4 43 3.4 ND < 10 mg/L
Thyroid stimulating hormone 1.7 ND ND ND 0.5-5 mU/L
Figure 1 Chest X-rays in supine position at one-week interval 
showing (A) porotic kyphosis and (B) camptocomic posture.Robert et al. Journal of Medical Case Reports 2010, 4:192
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toxicity [6-8]. In our case, there is a high index of suspi-
cion for the accountability of olanzapine in muscle dam-
a g e .  B a s e d  o n  p r e v i o u s  r e p o r t e d  c a s e s ,  t e m p o r a l
connection between exposure to the drug and onset of
symptoms, evidence for paraspinal muscle damage on
MRI, favorable outcome after discontinuation of the
drug, and lack of alternative explanation, we believe that
rhabdomyolisis leading to camptocormia was probably
induced by olanzapine in our patient [7]. A long term
side-effect of haloperidol is less probable as this treat-
ment was provided during ten years without problem.
Neuroleptic malignant syndrome may be evoked but nei-
ther hyperthermia nor cognitive changes were observed.
The combination of haloperidol and olanzapine muscle
toxicity may also be discussed.
It is thus debatable whether camptocormia relates
mainly to a dystonic disorder connected to Parkinson dis-
ease, or to a primary neuromuscular disorder [2]. The
"muscle theory" of camptocormia has mainly been devel-
oped in Europe, and there is evidence that, at least in
some cases, camptocormia relates to a primary neuro-
muscular disorder [1,3]. This is supported by muscle
changes on computed tomography scans or spinal MRI,
myopathic changes with fatty degeneration in biopsy
specimens and electromyograms of the paraspinal mus-
cles. In selected cases some improvement with steroid
treatment can be observed. Camptocormia may be asso-
ciated with a variety of neuromuscular disorders, such as
amyotrophic lateral sclerosis, focal myopathy, inflamma-
tory myositis including inclusion body myositis, and
some other heterogeneous muscular conditions [2,3,9-
12]. Laroche et al. (1995), basing their studies on a series
of 27 patients, argued that camptocormia in older adults
relates mainly to a genetically transmitted condition of
muscular dystrophy or myopathy restricted to the spinal
muscles [9]. However, the "central" and "peripheral" con-
cepts of the pathogenesis of camptocormia do not neces-
sarily contradict, as atrophy of the paraspinal muscles
m i g h t  b e  s e c o n d a r y  t o  a  p r i o r  a c t i o n  d y s t o n i a  o f  t h e
spine, as some recent studies have suggested [13].
Selected case reports and series indicate that both central
(dysfunction in basal ganglia) and peripheral (muscle
pathology) may coexist in patients with camptocormia
[10,13-15].
Conclusions
There is evidence from the literature that camptocormia
is a heterogeneous syndrome of various causes. We
be li eve t ha t  ou r case  il lust ra t es  t he  need t o sea r ch f o r
paraspinal muscle damage (including drug-induced rhab-
domyolysis) in patients presenting with acute-onset bent
spine syndrome. Although rare, the occurrence of camp-
tocormia induced by olanzapine must be considered.
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Figure 2 Dorso-lumbar spine magnetic resonance imaging, (A) coronal and (B) axial post gadolinium fat saturated T1: left major para-ver-
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